<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03640052</url>
  </required_header>
  <id_info>
    <org_study_id>2018P001201</org_study_id>
    <nct_id>NCT03640052</nct_id>
  </id_info>
  <brief_title>Pharmacological Activation of HMN for OSA</brief_title>
  <acronym>OSA12</acronym>
  <official_title>Pharmacological Activation of Hypoglossal Motor Nucleus for Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea (OSA) is common and has major health implications but treatment
      options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle
      activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared
      to normal subjects. In this protocol the investigators will test the effect of LTM1201L,
      LTM1201LN, LTM1201LB, LTM1201LD administered before sleep on OSA phenotype traits and OSA
      severity during sleep.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2018</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnea Hypopnea Index (AHI, Average Number of Events for Every Hour of Sleep)</measure>
    <time_frame>1 night</time_frame>
    <description>Based on previous studies the investigators anticipate that active comparators will reduce AHI more effectively in subjects with moderate sleep apnea and low-to-moderate collapsibility (Vpassive &gt;50% of eupneic values). Higher AHI indicates more severe OSA, usually ranging between 10 to 110 events/hour.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collapsibility of the Upper Airway: VActive (L/Min)</measure>
    <time_frame>1 night</time_frame>
    <description>VActive: ventilation when ventilatory drive is high and pharyngeal dilator muscles are relatively active.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule 1 time before bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LTM1201L</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LTM1201L capsule 1 time before bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LTM1201LN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LTM1201LN capsule 1 time before bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LTM1201LB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LTM1201LB capsule 1 time before bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LTM1201LD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LTM1201LD capsule 1 time before bedtime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo capsule before sleep</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTM1201L</intervention_name>
    <description>LTM1201L capsule before sleep</description>
    <arm_group_label>LTM1201L</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTM1201LN</intervention_name>
    <description>LTM1201LN capsule before sleep</description>
    <arm_group_label>LTM1201LN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTM1201LB</intervention_name>
    <description>LTM1201LB capsule before sleep</description>
    <arm_group_label>LTM1201LB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTM1201LD</intervention_name>
    <description>LTM1201LD capsule before sleep</description>
    <arm_group_label>LTM1201LD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AHI &gt; 10 events/h during NREM supine sleep

        Exclusion Criteria:

          -  Any medical condition other than well controlled hypertension and mild diabetes.

          -  Any medication known to influence breathing, sleep/arousal, or muscle physiology.

          -  Claustrophobia.

          -  Inability to sleep supine.

          -  Allergy to any of the medications tested in the protocol.

          -  History of kidney stones, hypercalcemia, primary hyperparathyroidism, sarcoidosis,
             hypervitaminosis D.

          -  Individuals with underlying cardiac disease, such as arrhythmias.

          -  Individuals taking psychiatric medications, such as an MAO-I, SSRI or SNRI, or any of
             the studied medications for medical care.

          -  For women: Pregnancy.

          -  Pulmonary hypertension

          -  Severe OSA with a mean SaO2 lower than 88%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Disorders Research Program Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <results_first_submitted>January 28, 2020</results_first_submitted>
  <results_first_submitted_qc>January 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 12, 2020</results_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Luigi Taranto Montemurro</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT03640052/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo First</title>
          <description>Placebo administered before sleep for 1 night, followed by LTM1201L, LTM1201LD, LTM1201LN and LTM1201LB, administered 1 week apart in the hospital</description>
        </group>
        <group group_id="P2">
          <title>LTM1201L First</title>
          <description>LTM1201L administered before sleep for 1 night, followed by LTM1201LD, LTM1201LN, LTM1201LB and Placebo, administered 1 week apart in the hospital</description>
        </group>
        <group group_id="P3">
          <title>LTM1201LD First</title>
          <description>LTM1201LD administered before sleep for 1 night, followed by LTM1201LN, LTM1201LB, Placebo and LTM1201L, administered 1 week apart in the hospital</description>
        </group>
        <group group_id="P4">
          <title>LTM1201LN First</title>
          <description>LTM1201LN administered before sleep for 1 night, followed by LTM1201LB, Placebo, LTM1201L and LTM1201LD administered 1 week apart in the hospital</description>
        </group>
        <group group_id="P5">
          <title>LTM1201LB First</title>
          <description>LTM1201LB administered before sleep for 1 night, followed by Placebo, LTM1201L, LTM1201LD and LTM1201LN administered 1 week apart in the hospital</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0">the patient performed 4 out of 5 nights</participants>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Analyzed Participants</title>
          <description>All participants who were randomized, completed both study nights, and were included in the analysis.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.5" lower_limit="47" upper_limit="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Apnea Hypopnea Index (AHI, Average Number of Events for Every Hour of Sleep)</title>
        <description>Based on previous studies the investigators anticipate that active comparators will reduce AHI more effectively in subjects with moderate sleep apnea and low-to-moderate collapsibility (Vpassive &gt;50% of eupneic values). Higher AHI indicates more severe OSA, usually ranging between 10 to 110 events/hour.</description>
        <time_frame>1 night</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsule 1 time before bedtime
Placebo oral capsule: Placebo capsule before sleep</description>
          </group>
          <group group_id="O2">
            <title>LTM1201L</title>
            <description>LTM1201L capsule 1 time before bedtime
LTM1201L: LTM1201L capsule before sleep</description>
          </group>
          <group group_id="O3">
            <title>LTM1201LN</title>
            <description>LTM1201LN capsule 1 time before bedtime
LTM1201LN: LTM1201LN capsule before sleep</description>
          </group>
          <group group_id="O4">
            <title>LTM1201LB</title>
            <description>LTM1201LB capsule 1 time before bedtime
LTM1201LB: LTM1201LB capsule before sleep</description>
          </group>
          <group group_id="O5">
            <title>LTM1201LD</title>
            <description>LTM1201LD capsule 1 time before bedtime
LTM1201LD: LTM1201LD capsule before sleep</description>
          </group>
        </group_list>
        <measure>
          <title>Apnea Hypopnea Index (AHI, Average Number of Events for Every Hour of Sleep)</title>
          <description>Based on previous studies the investigators anticipate that active comparators will reduce AHI more effectively in subjects with moderate sleep apnea and low-to-moderate collapsibility (Vpassive &gt;50% of eupneic values). Higher AHI indicates more severe OSA, usually ranging between 10 to 110 events/hour.</description>
          <units>events/hour of sleep</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="8"/>
                    <measurement group_id="O2" value="24.4" spread="11.3"/>
                    <measurement group_id="O3" value="18.8" spread="11.3"/>
                    <measurement group_id="O4" value="14" spread="11.3"/>
                    <measurement group_id="O5" value="9.1" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>mean difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.5</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.6</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>mean difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.5</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>mean difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.5</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-6.8</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>mean difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-11.7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Collapsibility of the Upper Airway: VActive (L/Min)</title>
        <description>VActive: ventilation when ventilatory drive is high and pharyngeal dilator muscles are relatively active.</description>
        <time_frame>1 night</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsule 1 time before bedtime
Placebo oral capsule: Placebo capsule before sleep</description>
          </group>
          <group group_id="O2">
            <title>LTM1201L</title>
            <description>LTM1201L capsule 1 time before bedtime
LTM1201L: LTM1201L capsule before sleep</description>
          </group>
          <group group_id="O3">
            <title>LTM1201LN</title>
            <description>LTM1201LN capsule 1 time before bedtime
LTM1201LN: LTM1201LN capsule before sleep</description>
          </group>
          <group group_id="O4">
            <title>LTM1201LB</title>
            <description>LTM1201LB capsule 1 time before bedtime
LTM1201LB: LTM1201LB capsule before sleep</description>
          </group>
          <group group_id="O5">
            <title>LTM1201LD</title>
            <description>LTM1201LD capsule 1 time before bedtime
LTM1201LD: LTM1201LD capsule before sleep</description>
          </group>
        </group_list>
        <measure>
          <title>Collapsibility of the Upper Airway: VActive (L/Min)</title>
          <description>VActive: ventilation when ventilatory drive is high and pharyngeal dilator muscles are relatively active.</description>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.657" spread="0.6865"/>
                    <measurement group_id="O2" value="3.856" spread="1.04"/>
                    <measurement group_id="O3" value="3.822" spread="1.049"/>
                    <measurement group_id="O4" value="6.008" spread="1.11"/>
                    <measurement group_id="O5" value="3.091" spread="1.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 night</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo capsule 1 time before bedtime
Placebo oral capsule: Placebo capsule before sleep</description>
        </group>
        <group group_id="E2">
          <title>LTM1201L</title>
          <description>LTM1201L capsule 1 time before bedtime
LTM1201L: LTM1201L capsule before sleep</description>
        </group>
        <group group_id="E3">
          <title>LTM1201LN</title>
          <description>LTM1201LN capsule 1 time before bedtime
LTM1201LN: LTM1201LN capsule before sleep</description>
        </group>
        <group group_id="E4">
          <title>LTM1201LB</title>
          <description>LTM1201LB capsule 1 time before bedtime
LTM1201LB: LTM1201LB capsule before sleep</description>
        </group>
        <group group_id="E5">
          <title>LTM1201LD</title>
          <description>LTM1201LD capsule 1 time before bedtime
LTM1201LD: LTM1201LD capsule before sleep</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <description>Dry mouth</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Luigi Taranto Montemurro, MD</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>6177326541</phone>
      <email>ltarantomontemurro@bwh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

